Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
Division of Hematology and Cell Therapy, Department of Internal Medicine III, Yamagata University School of Medicine, Yamagata, Japan.
Blood Adv. 2023 Nov 28;7(22):6936-6948. doi: 10.1182/bloodadvances.2023009721.
Acute kidney injury (AKI) is a frequent complication of allogeneic hematopoietic cell transplantation (allo-HCT). There are many causes of AKI after allo-HCT, but it is unknown whether renal acute graft-versus-host disease (aGVHD) caused by direct allogeneic donor T-cell-mediated renal damage contributes. Here, we tested whether allogeneic donor T cells attack kidneys in murine models of aGVHD. To avoid confounding effects of nephrotoxic agents, we did not administer immunosuppressants for GVHD prophylaxis. We found that urinary N-acetyl-β-D-glucosaminidase, a marker of tubular injury, was elevated in allogeneic recipients on day 14 after allogeneic bone marrow transplantation. Donor major histocompatibility complex-positive cells were present and CD3+ T cells were increased in the glomerulus, peritubular capillaries, interstitium, and perivascular areas in the kidneys of allo-HCT recipient mice. These T cells included both CD4+ and CD8+ cells with elevated activation markers, increased exhaustion markers, and greater secretion of proinflammatory cytokines and cytotoxic proteins. Consistent with allo-T-cell-mediated renal damage, expression of neutrophil gelatinase-binding lipocalin, a marker of AKI, and elafin, a marker of aGVHD, were increased in renal tissue of allogeneic recipients. Because apoptosis of target cells is observed on histopathology of aGVHD target tissues, we confirmed that alloreactive T cells increased apoptosis of renal endothelial and tubular epithelial cells in cytotoxic T-lymphocyte assays. These data suggest that immune responses induced by donor T cells contribute to renal endothelial and tubular epithelial cell injury in allo-HCT recipients and that aGVHD may contribute to AKI after allo-HCT.
急性肾损伤(AKI)是异基因造血细胞移植(allo-HCT)的常见并发症。allo-HCT 后 AKI 有许多原因,但尚不清楚直接同种异体供体 T 细胞介导的肾损伤引起的急性移植物抗宿主病(aGVHD)是否起作用。在这里,我们测试了同种异体供体 T 细胞是否在 aGVHD 的小鼠模型中攻击肾脏。为避免肾毒性药物的混杂影响,我们没有进行预防 GVHD 的免疫抑制治疗。我们发现,在异基因骨髓移植后 14 天,同种异体受者的尿 N-乙酰-β-D-氨基葡萄糖苷酶(一种肾小管损伤的标志物)升高。在 allo-HCT 受者小鼠的肾脏中,肾小球、肾小管周围毛细血管、间质和血管周围区域存在供体主要组织相容性复合体阳性细胞,并且 CD3+T 细胞增加。这些 T 细胞包括 CD4+和 CD8+细胞,其激活标志物升高,衰竭标志物增加,促炎细胞因子和细胞毒性蛋白的分泌增加。与同种异体 T 细胞介导的肾损伤一致,AKI 的标志物中性粒细胞明胶酶相关载脂蛋白和 aGVHD 的标志物 elafin 在同种异体受者的肾脏组织中表达增加。由于在 aGVHD 靶组织的组织病理学上观察到靶细胞的凋亡,我们在细胞毒性 T 淋巴细胞测定中证实同种反应性 T 细胞增加了肾脏内皮细胞和肾小管上皮细胞的凋亡。这些数据表明,供体 T 细胞诱导的免疫反应导致 allo-HCT 受者的肾内皮和肾小管上皮细胞损伤,并且 aGVHD 可能导致 allo-HCT 后的 AKI。